( 00 ETEC E. coli vaccine VLPs andothe...)Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical,Potential,Health

00, ETEC E. coli vaccine, VLPs and other products and AVANT’s expectations regarding market growth; (4) the cost, timing, scope and results of ongoing safety and efficacy trials of CholeraGarde® (Peru-15), Ty800, ETEC E. coli vaccine and other preclinical and clinical testing; (5) the ability to negotiate strategic partnerships or other disposition transactions for AVANT’s cardiovascular programs, including TP10 and CETi; (6) the ability of AVANT to manage multiple clinical trials for a variety of product candidates; (7) AVANT’s expectations regarding its technological capabilities and expanding its focus to broader markets for vaccines; (8) the Company’s expectations regarding the cost of funding its development partnership with Select Vaccines Limited for the influenza vaccine, the opportunity to extend to other disease targets, and AVANT’s ability to develop products through this collaboration; (9) changes in existing and potential relationships with corporate collaborators; (10) the availability, cost, delivery and quality of clinical and commercial grade materials produced at AVANT’s own Manufacturing facility or supplied by contract manufacturers and partners; (11) the timing, cost and uncertainty of obtaining regulatory approvals; (12) the ability to develop and commercialize products before competitors that are superior to the alternatives developed by competitors; (13) the ability to retain certain members of management;(14) AVANT’s expectations regarding research and development expenses and general and administrative expenses; (15) AVANT’s expectations regarding cash balances, capital requirements, anticipated royalty payments (including those from Paul Royalty Fund), revenues and expenses, including infrastructure expenses; (16) our belief regarding the validity of our patents and potential litigation; and (17) certain other factors that might cause AVANT’s actual results to differ materially from
'"/>




Page: 1 2 3 4 5
Related medicine technology :

1. Avants Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential
2. SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193
3. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
7. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
8. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
9. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
10. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
11. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference